Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

 

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

An Executive Informational Overview (EIO) is now available on Celsion Corporation, a fully integrated biopharmaceutical company focused on developing cancer therapies for difficult-to-treat forms of cancers. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: biotech, immunotherapy, cancer, autoimmune, hepatocellular cancer, GEN-1, ovarian cancer, interleukin-12, IL-12, ThermoDox, primary liver cancer, celsion

Crystal Research Associates has issued a 12-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ).

 

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued an 84-page Updated Executive Informational Overview (EIO) on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Topics: geovax

Crystal Research Associates has issued an 11-page Quarterly Update on specialty biotech pharmaceutical research and development (R&D) company, FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE), detailing the Company's recent news and developments—including its recent permission from the U.S. FDA on June 1, 2020 to submit an Investigational New Drug Application (IND) to use FSD201 to treat COVID-19 (the disease caused by the SARS-CoV-2 virus)—as well as its recent financial position. The report is available for download below.

Topics: Cannabis, fsd pharma, Endocannabinoid System (ECS), Palmitolylethonalamide (PEA), ultramicronized-PEA, fsd, FSD201, medical cannabis, covid19, coronovirus

An Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 86-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia

An Executive Informational Overview (EIO) is now available on StageZero Life Sciences, Ltd (SZLS-TSX), a revenue-generating innovator in the liquid biopsy space, dedicated to the early detection of cancer and multiple disease states. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: liquid biopsy, blood-based diagnostics, ColonSentry, Sentinel Principle, EarlyCDT®-Lung, BreastSentry, StageZero Life Sciences

An Executive Informational Overview (EIO) is now available on FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE), a specialty biotech pharmaceutical company focused on developing FDA-approved synthetic compounds targeting the endocannabinoid system (ECS) of the human body. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: Cannabis, fsd pharma, Endocannabinoid System (ECS), Palmitolylethonalamide (PEA), Prismic Pharmaceuticals, ultramicronized-PEA, fsd, SciCann Therapeutics, Solarvest BioEnergy Inc., FSD201, medical cannabis, Canntab Therapeutics Ltd, Huge Shops, Aura Health Inc.

An Executive Informational Overview (EIO) is now available on Reliance Global Group, Inc. (RELI-OTC), a diversified holding company investing in real estate and insurance markets. The 48-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: reliance global group, multi-family properties, insurance, insurance carriers, Employee Benefit Solutions, The Referral Depot, reliance global holdings, RELI, insurance agencies, REIT, real estate, U.S. Benefits Alliance, Commercial Solutions of Insurance Agency, Southwestern Montana Insurance Center, Fortman Insurance Agency

Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVXD-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

CVR Medical Corp. announced that it will have its upcoming “Carotid Stenotic Scan (CSS)” device showcased by its manufacturing and strategic partner Canon Virginia, Inc. (CVI), a wholly owned subsidiary of Canon USA, at this week’s Medical Design & Manufacturing West (MD&M) in Anaheim, CA. CVR Medical's CSS is a novel device that uses patented sound wave analysis technology to detect and measure carotid arterial stenosis.

MD&M West is recognized as the main and most comprehensive yearly medical technology and manufacturing expo and conference in North America (https://mdmwest.mddionline.com). From February 5-7, 2019, over 19,000 members of the global medical care and manufacturing community will gather at MD&M West to learn about and exhibit the latest in cutting-edge advancements.

 CVR has partnered with CVI for the manufacturing, supply chain management, logistics, white glove delivery to end user, telephone tech support, and on-site service for the CSS; providing key advantages when CVR scales to meet potential global demand.

With Canon as a recognized leader in imaging technology, CVR gains invaluable exposure and credibility within the industry. Canon’s showcase of the CSS highlights the unique, customized manufacturing of the device, as well as logistics and product support needs. The manufacturing partnership between CVR Medical and Canon, announced in 2017, established the production means through which the CSS will be launched.

****************************************************** 

Learn move about CVR Medical by downloading our Executive Informational Overview (EIO), a 60-page report detailing the Company's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more.

Topics: cvr medical, carotid health, ischemic stroke, occlusion, duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA), computed tomography angiography (CTA), cerebral angiogram, Henry Ford Hospital, Cleveland Clinic, Canon U.S.A., transient ischemic attack (TIA), medical technology company, Carotid Stenotic Scan (CSS), stenosis, stroke, Thomas Jefferson University Hospital, ENTICES Study, CVM-TSX, CRRVF-OTCQB, atherosclerosis, Army Research Lab

GeoVax announced that it has been nominated for the 2019 ViE (Vaccine Industry Excellence) Awards in three categories. Please use the following link to vote for these special industry awards in the follow categories:

https://www.surveymonkey.co.uk/r/J39ZFW3

• Best Vaccine Technology/Platform
• Best Therapeutic Vaccine
• Best Prophylactic Vaccine
  

GeoVax's development programs are importantly focused on vaccines against HIV as well as Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy and for therapeutic use in chronic Hepatitis B infections. .

For more information on GeoVax, please read to our most recent Quarterly Update dated November 14, 2018, as well as our Executive Informational Overview (EIO), issued on June 15, 2017 and available for download below.

 

 

*******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv

CVR Medical Corp. announced today that it has completed a Food and Drug Administration De Novo Submission for its “Carotid Stenotic Scan (CSS)” device.  A De Novo Submission allows for a company to receive a “not substantially equivalent” risk-based evaluation for any legally marketed device for which there is no prior, comparable classification. 

The Company's CSS, which is a novel device that uses patented sound wave analysis technology to detect and measure carotid arterial stenosis, fits within the criteria of this FDA filing. Due to U.S. government shutdown, the submission will be reviewed by the FDA upon resumption of government activity.
 
CVR's FDA submission marks the culmination of the Company's many years of product development, design, trials, and organizational preparation, and is necessary for any new device entering the market.

****************************************************** 

Learn move about CVR Medical by downloading our Executive Informational Overview (EIO), a 60-page report detailing the Company's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more.

Topics: cvr medical, carotid health, ischemic stroke, occlusion, duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA), computed tomography angiography (CTA), cerebral angiogram, Henry Ford Hospital, Cleveland Clinic, Canon U.S.A., transient ischemic attack (TIA), medical technology company, Carotid Stenotic Scan (CSS), stenosis, stroke, Thomas Jefferson University Hospital, ENTICES Study, CVM-TSX, CRRVF-OTCQB, atherosclerosis, Army Research Lab

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv